ライフサイエンスコーパス: second-line therapy

1 , gefitinib, or pemetrexed is recommended as second-line therapy.

2 milar toxicity rates and are appropriate for second-line therapy.

3 l use of either irinotecan or oxaliplatin as second-line therapy.

4 tients received irinotecan-based regimens as second-line therapy.

5 taxel and ifosfamide plus cisplatin (TIP) as second-line therapy.

6 in the future, and so will remain as a weak second-line therapy.

7 Half the cohort received ZD1839 as second-line therapy.

8 portions of patients in both groups received second-line therapy.

9 eekly docetaxel and trastuzumab as first- or second-line therapy.

10 taxel and ifosfamide plus cisplatin (TIP) as second-line therapy.

11 cythaemia vera without splenomegaly who need second-line therapy.

12 alive and in remission following successful second-line therapy.

13 st dose of etoposide-containing frontline or second-line therapy.

14 examethasone independently prolonged time to second-line therapy.

15 ming virological failure before switching to second-line therapy.

16 d Drug Administration of PD-1 inhibitors for second-line therapy.

17 ent treatment with nilotinib or dasatinib as second-line therapy.

18 ear or less, and progressive disease despite second-line therapy.

19 failure of these drugs; there is no approved second-line therapy.

20 irst-line setting and anetumab ravtansine as second-line therapy.

21 ained efficacy in BRAF(V600E)-mutated ECD as second-line therapy.

22 mproved patient counseling and selection for second-line therapy.

23 was overall survival since the initiation of second-line therapy.

24 to evaluate the efficacy of CA as first- or second-line therapy.

25 ay influence clinician and patient choice of second-line therapy.

26 lar definitions are provided for response to second-line therapy.

27 patient who developed t-AML/MDS did so after second-line therapy.

28 n receptor agonists (TPO-RAs) as options for second-line therapy.

29 t-line therapy, or tramadol or duloxetine as second-line therapy.

30 00 mg/m(2) once every 21 days) as predefined second-line therapy.

31 quiring a switch to protease inhibitor-based second-line therapy.

32 gression received the alternative regimen as second-line therapy.

33 p alternative first-line regimens and better second-line therapies.

34 months, but patients are rarely switched to second-line therapies.

35 and with different criteria for switching to second-line therapies.

36 E) that continued despite initial first- and second-line therapies.

37 ere sputum culture-positive at initiation of second-line therapy, 129 (77%) converted in a median tim

38 Only 45% of patients received second-line therapy (42% in arm A v 47% in arm B, P =.42

39 trate/5-FU combination responded to M-VAC as second-line therapy (42%; 95% CI, 15.2% to 72.3%).

40 mately 75% of patients in both arms received second-line therapy; 58% of rIFL patients received oxali

41 e 135 patients who received the treatment as second-line therapy, 94 were disease-free during follow-

42 ates antitumor activity in metastatic RCC as second-line therapy, a setting where no effective system

43 Four cycles of TIP as second-line therapy achieved a durable CR rate in a high

44 Ninety-two patients (35%) needed second-line therapy after a median of 49 months.

45 Patients with AL amyloidosis who need second-line therapy after response to up-front treatment

46 Toremifene is not likely to be used as second-line therapy after tamoxifen failure due to cross

47 metrexed, have shown significant activity as second-line therapy and are currently being evaluated in

48 This review discusses current second-line therapy and emerging drugs for advanced tran

49 rrelate the percentage of patients receiving second-line therapy and the percentage of patients recei

50 by resistance testing, of the NRTIs used in second-line therapy and treatment outcomes for patients

51 , considerations in the choice of first- and second-line therapies, and the management of patients af

52 of rIFL patients received oxaliplatin-based second-line therapy, and 55% of FOLFOX4 patients receive

53 Treatment with alkylating agents, second-line therapy, and age older than 35 years at trea

54 omisation was stratified by age, response to second-line therapy, and prognostic factors.

55 The advantages and disadvantages of these second line therapies are reviewed.

56 nalysis, we have shown that the responses to second-line therapies are durable.

57 ts offering an improved toxicity profile for second-line therapy are emerging.

58 st follow-up evaluation or the initiation of second-line therapy are included.

59 ons available to ovarian cancer patients for second-line therapy are limited, and knowing that mechan

60 r agents active in ovarian cancer for use as second-line therapy are warranted.

61 31%; and (5) suboptimal response to ASCT and second-line therapy as consolidation, 4%.

62 ing clarified and include a lack of standard second-line therapy as well as uncertain benefits for th

63 high-risk patients for closer monitoring and second-line therapies, as well as low-risk patients who

64 py, OS does not significantly differ whether second-line therapy begins with irinotecan or FOLFOX4.

65 s, VEGF receptors, PDGFR-beta, and c-KIT, as second-line therapy both in patients with FGFR2-mutated

66 Approximately 22% of patients receiving second-line therapy do not achieve HIV RNA suppression b

67 yclosporine may be an important component of second-line therapy due to its efficacy in controlling u

68 ith seizure termination after first-line and second-line therapies, episodes of CSE lasting for longe

69 l therapy; however, no standard approach for second-line therapy exists.

70 In second-line therapy, fludarabine induced a significantly

71 AR drug may be used as an alternative second line therapy for treating HER2 + BC.

72 Fenofibrate and bezafibrate are reasonable second-line therapies for dyslipidaemia and in diabetes,

73 Fenofibrate and bezafibrate are reasonable second-line therapies for dyslipidaemia and in diabetes.

74 ment has been accepted widely for the first-/second-line therapy for advanced gastric cancer (AGC).

75 etinib + docetaxel with docetaxel alone as a second-line therapy for advanced KRAS-mutant NSCLC.

76 rospective phase II studies as first-line or second-line therapy for advanced uterine leiomyosarcoma.

77 he regimen is a good choice as first-line or second-line therapy for advanced uterine leiomyosarcoma.

78 o 12 months of rhythm control when used as a second-line therapy for atrial fibrillation in relativel

79 Photodynamic therapy is proposed as a second-line therapy for bacille Calmette-Guerin failures

80 agents are used with a protease inhibitor in second-line therapy for human immunodeficiency virus (HI

81 l frontline therapy (hydroxyurea or IFN) and second-line therapy for hydroxyurea-refractory or intole

82 combination regimen was active as first- or second-line therapy for metastatic breast cancer, althou

83 r receptor 2, MET, and AXL and is a standard second-line therapy for metastatic renal cell carcinoma

84 y and safety of docetaxel plus nintedanib as second-line therapy for non-small-cell lung cancer (NSCL

85 r trial of biweekly 72 hour 9-AC infusion as second-line therapy for ovarian cancer demonstrates comp

86 lypeptide capreomycin are all widely used in second-line therapy for patients who develop multidrug-r

87 nt profile of sunitinib as a single agent in second-line therapy for patients with cytokine-refractor

88 reverse-transcriptase inhibitors (NRTIs) in second-line therapy for patients with HIV, but evidence

89 The drug also has been approved as second-line therapy for polycythemia vera (PV).

90 y indicates that gene transfer as a first or second-line therapy for practicing urologists would be w

91 e methotrexate (MTX) remains the mainstay of second-line therapy for rheumatoid arthritis (RA).

92 tiarrhythmic drug therapy both as first- and second-line therapy for the maintenance of sinus rhythm

93 ity and efficacy of sirolimus (rapamycin) as second-line therapy for the treatment of acute graft-ver

94 hionamide (ETA) is an important component of second-line therapy for the treatment of multidrug-resis

95 most practitioners in the USA use IVIG as a second-line therapy for those Kawasaki disease patients

96 Corticosteroids are a second-line therapy for those who do not respond, are in

97 As second-line therapy, fulvestrant should be administered

98 For second-line therapy, gemcitabine plus NAB-paclitaxel sho

99 wo hundred patients potentially eligible for second-line therapy had a PSS of 5.3 (4.6-7.1) months, w

100 Patients who did not receive the alternative second-line therapy had better overall survival with fir

101 tients with organ progression at the time of second-line therapy had inferior survival.

102 carcinoma, patients treated with axitinib as second-line therapy had longer median progression-free s

103 rapy (with at least a partial response after second-line therapy); had received a purine analogue, be

104 n modest but consistent; however, gains from second-line therapies have been disappointing.

105 As second-line therapy, he received interferon alfa-2b (IFN

106 To be a viable option for first- or second-line therapy, however, its cost must approach tha

107 atients were considered to have responded to second-line therapy if they satisfied specific criteria,

108 with a short course of steroids as first- or second-line therapy in 23 patients with primary autoimmu

109 l survival versus placebo plus paclitaxel as second-line therapy in a phase 2 study in Asian patients

110 01) with approximately 80% response rates to second-line therapy in either arm, including autologous

111 observed therapy would improve outcomes with second-line therapy in HIV-infected patients for whom fi

112 terferon alfa-2b (IFN-alpha-2b) as first- or second-line therapy in metastatic renal cell cancer (RCC

113 r (VEGF) and steroids is currently used as a second-line therapy in patients not responding to monoth

114 Hypoglossal nerve stimulation is a useful second-line therapy in patients who cannot tolerate cont

115 Purpose The standard of care for second-line therapy in patients with advanced pancreatic

116 maintenance therapy after chemotherapy-based second-line therapy in patients with chronic lymphocytic

117 be evaluated in larger studies as first- or second-line therapy in patients with hepatic metastases

118 nib, an approved VEGF receptor inhibitor, as second-line therapy in patients with metastatic renal ce

119 e-day topotecan infusion was administered as second-line therapy in patients with previously treated

120 lastine, ifosfamide, and cisplatin (VeIP) as second-line therapy in patients with recurrent germ cell

121 body against CD20, combined with ICE or DHAP second-line therapy in patients with relapsed or refract

122 and cycloplegics as first-line methods; the second-line therapy in pseudophakic eyes was laser hyalo

123 l and resistance outcomes of those receiving second-line therapy in resource-limited settings.

124 athy, and multifocal motor neuropathy and as second-line therapy in stiff-person syndrome, dermatomyo

125 ll be used in up to 2 million individuals as second-line therapy in sub Saharan Africa by 2020.

126 and/or when treatment was given as first- or second-line therapy in the metastatic setting.

127 .8% of all patients who received any sort of second-line therapy in the TMZ arm.

128 b could be considered a standard of care for second-line therapy in this post-hydroxyurea patient pop

129 subsequent treatment, with special focus on second-line therapy, in the FIRE-3 trial (FOLFIRI plus c

130 involves trimethoprim-sulfamethoxazole, with second-line therapies, including atovaquone, dapsone, an

131 arator), 3 infliximab infusions + 6MP/met as second-line therapy (intervention I), infliximab with ep

132 ntervention II), and 6MP/met + infliximab as second-line therapy (intervention III).

133 Splenectomy is usually proposed when a second-line therapy is needed.

134 r than in 23 ALK-positive controls given any second-line therapy (median overall survival not reached

135 When given with a protease inhibitor in second-line therapy, NRTIs retained substantial virologi

136 Axitinib is a treatment option for second-line therapy of advanced renal cell carcinoma.

137 pean centers, rituximab is now the preferred second-line therapy of warm antibody hemolytic anemia in

138 , had a shorter survival after initiation of second-line therapy on univariate, but not on multivaria

139 toring and, when detected, largely preserves second-line therapy options.

140 ts should be confined to first-line therapy, second-line therapy or both.

141 the percentage of patients who received any second-line therapy (P =.19).

142 nd an acceptable safety profile when used as second-line therapy patients with platinum-refractory SC

143 Second-line therapy produced only partial responses, and

144 g the association of a probiotic compound to second-line therapy regimen.

145 isk of death was associated with response to second-line therapy (relative risk, 0.14; 95% CI, 0.05 t

146 rved in 22% and 12% of patients who received second-line therapy, respectively.

147 ant subpopulation, whereas poor adherence or second-line therapy resulted in the reemergence of the d

148 As second-line therapy, splenectomy and Rituximab are both

149 ents who received the alternative regimen as second-line therapy, the median duration of progression-

150 Second-line therapy typically includes multiagent chemot

151 The median time from ASCT to second-line therapy was 24.3 months.

152 Second-line therapy was administered for a median durati

153 tment with intravenous phenytoin (n=32) as a second-line therapy was associated with a 9 times (95% C

154 Second-line therapy was given to the remaining 100 patie

155 Response to second-line therapy was PD in 34 and SD/MR in 66.

156 Second-line therapy was successful in approximately 60%

157 % CI, 0.55 to 0.88; P = .0021) from start of second-line therapy were longer in patients in arm A com

158 prior cytogenetic response on imatinib or on second-line therapy were the only independent predictors

159 ecan and paclitaxel have similar activity as second-line therapies with regard to response rates and

160 hree hundred three patients received HDCT as second-line therapy with a 2-year PFS of 63% (95% CI, 57

161 ed in volume, mice (n = 18) were assigned to second-line therapy with letrozole (100 microg/d; n = 6)